AKT1 and type 2 diabetes mellitus: Acarbose (α-glucosidase inhibitor), a widely used oral glucose-lowering drug exclusively for T2DM, increased circulating EPC number and NO production, thus also exhibiting potential as a therapeutic for promoting wound healing and improving angiogenesis in db/db mice, which may be related to activation of Akt/eNOS signaling (Han et al., 2017).